Educational Video Series


Robert Arceci, MD, PhD

Robert Arceci

Dr. Arceci completed his undergraduate studies at Trinity College, received his Ph.D. and M.D. from the University of Rochester, and then completed his Residency in Pediatrics and Fellowship in Pediatric Hematology/Oncology at The Children’s Hospital, Boston and Harvard Medical School.  Following faculty appointments at Harvard Medical School, the Dana Farber Cancer Institute and Boston Children’s Hospital, he became Director of Pediatric Hematology/Oncology at Children’s Hospital Medical Center in Cincinnati.  In 2000, Dr. Arceci became Director and King Fahd Professor of Pediatric Oncology and Professor of Oncology and Pediatrics at the Johns Hopkins University School of Medicine.  He served as Director, Children’s Center for Cancer and Blood Disorders Hematology/Oncology at Phoenix Children’s Hospital and the University of Arizona College of Medicine, Phoenix as well as Co-Director of the Ron Matricaria Institute of Molecular Medicine until his unexpected passing in June 2015.

Dr. Arceci was a member of numerous scientific and medical societies, advisory committees and review boards, and had been the recipient of several prestigious honors and awards.  He was the author of a large number of published scholarly works and served as a reviewer for several distinguished journals.  He was considered an international authority in many challenging areas of clinical pediatric oncology including the diagnosis and treatment of Leukemia and Langerhans Cell Histiocytosis.  He had served on a variety of committees in the Pediatric Oncology Group, the Children’s Cancer Group and the Children’s Oncology Group, including Chairperson for the Myeloid Leukemia Committee and Vice-Chair of the Biology and Therapeutics Translational Committee.  Dr. Arceci was Editor-in-Chief of Pediatric Blood and Cancer and had previously served as Editor-in-Chief of the Journal of Pediatric Hematology/Oncology and Associate Editor of the Journal of Pediatrics.  He was the editor of several textbooks, the most recent, Pediatric Hematology, along with co-editors, Ian Hann and Owen Smith, Targeted Therapy in Pediatric Cancer with co-editor, Peter Houghton, and served as editor of the oncology section of the most recent Rudolf’s Pediatrics.  He was a co-editor of a textbook in preparation titled, Cancer Genomics.  He had been a Leukemia/Lymphoma Society translational researcher.  He continued to be actively involved in defining optimal health care models as well as educational initiatives and had received several teaching awards and given the While Coat Lecture at the 2009 Johns Hopkins ceremony. He was the originator of the internationally acclaimed movie on childhood cancer, A Lion in the House, filmed by documentary filmmakers Steven Bognar and Julia Reichert.

A physician/scientist who had concentrated his work on basic and translational research in pediatric hematology and oncology, Dr. Arceci's focus continued on discovery and implementation of basic science to improve the comprehensive care for children and adolescents with cancer. He had been particularly involved in the development of novel therapeutic targets and immunotherapies to improve outcomes while reducing adverse side effects in children and adults with leukemia and histiocytic disorders.  A large part of his focus was to bring together teams of multidisciplinary groups of investigators to develop scientifically robust and interactive environments for molecularly based, individualized treatment.   

 

 

View Dr. Arceci's video: Overview of Erdheim-Chester Disease
Return to Educational Video Series page

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
| info@histio.org
Privacy | DisclaimerState Fundraising Notices 
Tax ID: 22-2827069 | Contact Us 
Follow Me on Pinterest   


¿No Habla Inglés? Si usted puede escribirme sus preguntas y preocupaciones a la dirección de correo electrónico: outreach@histio.org. Nosotros podremos responderle tan pronto nos sea possible. Gracias!